Results 201 to 210 of about 12,390,722 (231)
Some of the next articles are maybe not open access.
BET-inhibition by JQ1 alleviates streptozotocin-induced diabetic cardiomyopathy
Toxicology and Applied Pharmacology, 2018Diabetic cardiomyopathy is a cascade of complex events leading to eventual heart failure in diabetes. JQ1, one of Bromodomain and extra-terminal domain (BET) protein inhibitors, has exerted therapeutic effects on cancer proliferation, inflammation and cardiovascular disease.
Miao, Guo, Hong-Xia, Wang, Wen-Jun, Chen
openaire +2 more sources
Synthesis, SAR, and application of JQ1 analogs as PROTACs for cancer therapy
Bioorganic and Medicinal ChemistryJQ1 is a wonder therapeutic molecule that selectively inhibits the BRD4 signaling pathway and is thus widely used in the anticancer drug discovery program. Due to its unique selective BRD4 binding property, its applications are further extended in the design and synthesis of bi-functional PROTAC molecules.
Raghaba Sahu, Shubhendu Palei, Soumik De
exaly +3 more sources
SOX9 is controlled by the BRD4 inhibitor JQ1 via multiple regulation mechanisms
Biochemical and Biophysical Research Communications, 2019SOX9 is a key transcription factor during cell differentiation, sex determination, and tumorigenesis. However, the detailed mechanisms of its targeting strategy remain elusive. To investigate possibilities of targeting SOX9 with epigenetic drugs and the precise underlying mechanisms, two human cancer cell lines were chosen as model systems, which ...
Seong Hwi Hong, Jueng Soo You
openaire +2 more sources
JQ1, a Potential Therapeutic Molecule for Myeloid Leukemia with PTEN Deficiency
Blood, 2016Abstract Acute myeloid leukemia (AML) is a hematologic malignancy that continues to have high relapse and treatment-related mortality rates, despite recent advances in clinical management and therapy. Janus kinase (JAK) inhibitors inhibit the activity of the JAK/STAT pathway and have demonstrated some clinical responses in AML patients ...
Nicholas J Baltz +8 more
openaire +1 more source
The Minor Planet Electronic Circulars contain information on unusual minor planets, routine data on comets and natural satellites, and occasional editorial announcements. They are published on behalf of Division F of the International Astronomical Union by the Minor Planet Center, Smithsonian Astrophysical Observatory, Cambridge, MA 02138, U.S.A.
openaire +1 more source
openaire +1 more source
The Minor Planet Electronic Circulars contain information on unusual minor planets, routine data on comets and natural satellites, and occasional editorial announcements. They are published on behalf of Division F of the International Astronomical Union by the Minor Planet Center, Smithsonian Astrophysical Observatory, Cambridge, MA 02138, U.S.A.
openaire +1 more source
openaire +1 more source
The Minor Planet Electronic Circulars contain information on unusual minor planets, routine data on comets and natural satellites, and occasional editorial announcements. They are published on behalf of Division F of the International Astronomical Union by the Minor Planet Center, Smithsonian Astrophysical Observatory, Cambridge, MA 02138, U.S.A.
openaire +1 more source
openaire +1 more source
Bromodomain inhibitors, JQ1 and I-BET 762, as potential therapies for pancreatic cancer
Cancer Letters, 2017Bromodomain inhibitors (JQ1 and I-BET 762) are a new generation of selective, small molecule inhibitors that target BET (bromodomain and extra terminal) proteins. By impairing their ability to bind to acetylated lysines on histones, bromodomain inhibitors interfere with transcriptional initiation and elongation.
Ana S, Leal +5 more
openaire +2 more sources
Synergy between arsenic trioxide and JQ1 on autophagy in pancreatic cancer.
Oncogene, 2020Pancreatic cancer is a deadliest type of malignancy and lacks effective intervention. We here report a potential strategy for treatment of this malignancy by the combination of arsenic trioxide (ATO) and BET bromodomain inhibitor JQ1. These two agents synergistically modulate multistages of autophagy and thus induce apoptosis effectively in pancreatic ...
Congling, Xu +9 more
openaire +1 more source
Combination Therapy with the Epigenetic Drugs JQ1 and SAHA Inhibits PDAC
Cancer Discovery, 2015Abstract Dual inhibition of BET proteins and HDACs synergistically suppresses PDAC development and maintenance.
openaire +1 more source